Articles By Janet Pope, MD, MPH, FRCPC
Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?
Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).
Read Article
We Measure What we do in RA, But so What?
We are supposed to treat to a target (T2T) in RA. In other words, measure many components of the disease and its activity and calculate a score and if the patient is not in remission (or a low state if remission is not achievable) we are to make a treatment change.
Read Article
Does RA kill you? Let me count the ways….and what you can do about it
There were many presentations at EULAR 2018 in Amsterdam about the mortality of RA.
Read Article
The Gender Gap in Rheumatology Leaders
Leadership positions in medicine are disproportionately filled by men. Although the enrollment of medical schools are equal male: female or even some have more women, 40% of American medical institutions lack programs for recruiting women, or for retention and promotion of female faculty.This may also be true in rheumatology, which is now attracting more women than men as trainees. I recently wrote an article in the Lancet about mentoring women in medicine and suggested ideas for improving the gender gap in leadership.
Read Article
Highlights from EULAR 2017 - From RheumReports.com
Dr. Janet Pope reviews her favorite and least favorite presentations and abstracts from EULAR 2017.
Read Article
Why Not Just Kick the TNFi Habit?
Why do we use TNF inhibitors as our first biologic choice? Is it the evidence of efficacy, access, safety, and drug retention, or is it a prescriber habit that merits critique?
Read Article
Smoking and Rheumatoid Arthritis
Why don't rheumatologists send their smoker patients to smoking cessation programs or use aids for cessation? Do we think it is not our problem?
Read ArticleRA Guidelines Shouldn't Ignore the Power of Methotrexate Combo Therapy
The introduction of the 2015 rheumatoid arthritis treatment guidelines has prompted discussion and critique from many. Here's my perspective on where monotherapy and methotrexate combination therapy fits in our armamentarium.
Read Article
How Do I Treat Symptomatic Interstitial Lung Disease in Scleroderma?
Will the results of two recent large scleroderma lung studies finally inform us on how to manage interstitial lung disease in systemic sclerosis?
Read Article